[Comparison of immunological reconstitution and related complications after HLA-matched and HLA haploidentical peripheral blood hematopoietic stem cell transplantation].
OBJECTIVE
To explore the difference of immune function and relationship with main complications after HLA-matched and HLA haploidentical allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT).


METHODS
Sixty-seven patients undergoing HLA-matched (n = 33) or HLA haploidentical (n = 34) allo-PBSCT during the same time period in our hospital from June 2004 to December 2007 were included in this study. Indirect immunofluorescence assay was employed to detect lymphocyte subsets before transplantation and on month 1, 3, 6, 12 and 18 after transplantation and the lymphocyte subsets of 100 healthy people were used as normal control. The comparison of immunological reconstitution and relationship with main complications was carried out with statistical analysis.


RESULTS
(1) Comparison of the 67 patients with normal controls showed that CD(3)(+), CD(4)(+), CD(4)(+)/CD(8)(+) at month 1, CD(4)(+), CD(4)(+)/CD(8)(+) at month 3 and CD(4)(+) at month 6 after PBSCT were lower. CD(8)(+) at month 3 and month 6 were higher. (2) The immune function was not statistically different between HLA haploidentical and HLA-matched allo-PBSCT (P > 0.05). (3) The immune function of patients with and without severe infection was not statistically different (P > 0.05). (4) The immune function of patients with chronic graft-versus-host disease (cGVHD) between HLA haploidentical and HLA-matched allo-PBSCT groups was not statistically different. The immune function of patients without cGVHD in two groups was not statistically different (P > 0.05). (5) The immune function of patients with or without relapse was not statistically different (P > 0.05).


CONCLUSIONS
HLA-haploidentical PBSCT conditioning including antithymocyte globulin without in vitro T cell depletion is feasible and safe. The immunological reconstitution, incidence of severe infection, incidence of relapse and treatment-related mortality are not significantly different between HLA-matched and HLA haploidentical allo-PBSCT.
Li
Ling
L
Department of Hematology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830054, China.
Yuan
Hai-long
HL
Wen
Bing-zhao
BZ
Zhong
Di
D
Qu
Jian-hua
JH
Jiang
Ming
M
Halida
Yasen
Y
Guo
Xin-hong
XH
Hao
Jian-ping
JP
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006238:Haploidy; D006402:Hematologic Diseases / Q000235:genetics / Q000276:immunology / Q000601:surgery; D006801:Humans; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D055815:Young Adult
D006680:HLA Antigens